CN1039231C - 因子vii的纯化 - Google Patents

因子vii的纯化 Download PDF

Info

Publication number
CN1039231C
CN1039231C CN94191833A CN94191833A CN1039231C CN 1039231 C CN1039231 C CN 1039231C CN 94191833 A CN94191833 A CN 94191833A CN 94191833 A CN94191833 A CN 94191833A CN 1039231 C CN1039231 C CN 1039231C
Authority
CN
China
Prior art keywords
fvii
buffer solution
purification
activation
nacl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
CN94191833A
Other languages
English (en)
Chinese (zh)
Other versions
CN1121723A (zh
Inventor
T·朱尔根森
A·H·佩德森
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Novo Nordisk AS
Original Assignee
Novo Nordisk AS
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novo Nordisk AS filed Critical Novo Nordisk AS
Publication of CN1121723A publication Critical patent/CN1121723A/zh
Application granted granted Critical
Publication of CN1039231C publication Critical patent/CN1039231C/zh
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
    • C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
    • C12N9/64—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue
    • C12N9/6421—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue from mammals
    • C12N9/6424—Serine endopeptidases (3.4.21)
    • C12N9/6437—Coagulation factor VIIa (3.4.21.21)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y304/00—Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
    • C12Y304/21—Serine endopeptidases (3.4.21)
    • C12Y304/21021—Coagulation factor VIIa (3.4.21.21)

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Genetics & Genomics (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Biomedical Technology (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • General Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Molecular Biology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Catalysts (AREA)
  • Treatment Of Liquids With Adsorbents In General (AREA)
CN94191833A 1993-03-31 1994-03-24 因子vii的纯化 Expired - Fee Related CN1039231C (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DK93382A DK38293D0 (da) 1993-03-31 1993-03-31 Fremstilling af proteiner
DK382/93 1993-03-31

Publications (2)

Publication Number Publication Date
CN1121723A CN1121723A (zh) 1996-05-01
CN1039231C true CN1039231C (zh) 1998-07-22

Family

ID=8092871

Family Applications (1)

Application Number Title Priority Date Filing Date
CN94191833A Expired - Fee Related CN1039231C (zh) 1993-03-31 1994-03-24 因子vii的纯化

Country Status (16)

Country Link
US (1) US5700914A (enExample)
EP (1) EP0691984A1 (enExample)
JP (1) JPH08508264A (enExample)
CN (1) CN1039231C (enExample)
AU (1) AU677309B2 (enExample)
CA (1) CA2159313A1 (enExample)
CZ (1) CZ253395A3 (enExample)
DK (1) DK38293D0 (enExample)
FI (1) FI954649A0 (enExample)
HU (1) HUT72712A (enExample)
IL (1) IL109164A0 (enExample)
NO (1) NO953883L (enExample)
PL (1) PL310887A1 (enExample)
TW (1) TW278079B (enExample)
WO (1) WO1994022905A1 (enExample)
ZA (1) ZA941956B (enExample)

Families Citing this family (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE19538716A1 (de) * 1995-10-18 1997-04-24 Behringwerke Ag Verfahren zur Quantifizierung von aktiviertem Gerinnungsfaktor VII (FVIIa)
DE19538715A1 (de) 1995-10-18 1997-04-30 Behringwerke Ag Verfahren zur Reinigung von Faktor VII und aktiviertem Faktor VII
SI1308455T1 (sl) † 1998-05-06 2006-08-31 Genentech Inc Sestavek, ki obsega protitelesa anti-HER2
AT408613B (de) * 1998-06-17 2002-01-25 Immuno Ag Pharmazeutisches faktor vii-präparat
ATE428445T1 (de) 2000-02-11 2009-05-15 Bayer Healthcare Llc Gerinnungsfaktor vii oder viia konjugate
EP1458408B1 (en) 2001-12-21 2009-04-15 Novo Nordisk Health Care AG Liquid composition of factor vii polypeptides
US20040009918A1 (en) * 2002-05-03 2004-01-15 Hanne Nedergaard Stabilised solid compositions of modified factor VII
CA2490342C (en) 2002-06-21 2015-06-16 Novo Nordisk A/S Stabilised solid compositions of factor vii polypeptides
CA2519020A1 (en) 2003-03-18 2004-09-30 Novo Nordisk Health Care Ag Method for the production of gla-residue containing serine proteases
US7897734B2 (en) 2003-03-26 2011-03-01 Novo Nordisk Healthcare Ag Method for the production of proteins
DE602004025100D1 (de) * 2003-05-23 2010-03-04 Novo Nordisk Healthcare Ag Stabilisierung von proteinen in lösung
EP1641487B1 (en) 2003-06-25 2012-02-29 Novo Nordisk Health Care AG Liquid composition of factor vii polypeptides
ATE446768T1 (de) * 2003-07-01 2009-11-15 Novo Nordisk Healthcare Ag Flüssige wässrige pharmazeutische zusammnesetzung von factor vii polypeptiden
KR101293503B1 (ko) 2003-08-14 2013-08-07 노보 노르디스크 헬스 케어 악티엔게젤샤프트 인자 ｖｉｉ 폴리펩티드의 액상 수성 약학적 조성물
WO2005054275A2 (en) 2003-12-01 2005-06-16 Novo Nordisk Health Care Ag Nanofiltration of factor vii solutions to remove virus
CA2549593C (en) * 2003-12-19 2014-02-11 Novo Nordisk Health Care Ag Stabilised compositions of factor vii polypeptides
AU2005318106B2 (en) * 2004-12-23 2011-11-03 Novo Nordisk Health Care Ag Reduction of the content of protein contaminants in compositions comprising a Vitamin K-dependent protein of interest
DE602006015907D1 (de) * 2005-01-14 2010-09-16 Bayer Healthcare Llc Verfahren zur reinigung von factor vii
EP1907540B1 (en) * 2005-07-22 2012-12-19 Bayer HealthCare LLC In-solution activation of factor vii
US8841255B2 (en) 2005-12-20 2014-09-23 Duke University Therapeutic agents comprising fusions of vasoactive intestinal peptide and elastic peptides
WO2007073486A2 (en) * 2005-12-20 2007-06-28 Duke University Methods and compositions for delivering active agents with enhanced pharmacological properties
US20130172274A1 (en) 2005-12-20 2013-07-04 Duke University Methods and compositions for delivering active agents with enhanced pharmacological properties
US8178495B2 (en) 2008-06-27 2012-05-15 Duke University Therapeutic agents comprising a GLP-1 receptor agonist and elastin-like peptide
CN103539852B (zh) * 2012-07-12 2015-08-12 上海泰龙生物医药科技有限公司 一种从细胞培养液中分离纯化重组人凝血八因子的方法
EP2687595B1 (en) 2012-07-19 2018-05-30 Laboratoire Français du Fractionnement et des Biotechnologies Method for purifying transgenic factor VII
BR112015008666B1 (pt) 2012-10-17 2020-04-07 Procter & Gamble produto extensível para tratamento dental e método de aplicação de um ativo para tratamento bucal
US11059857B2 (en) 2016-12-22 2021-07-13 Km Biologics Co., Ltd. Chromatographic method for collecting blood coagulation factor VII with high yield

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0363126A2 (en) * 1988-10-04 1990-04-11 Eli Lilly And Company Method for the purification of vitamin K-dependent proteins

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0363126A2 (en) * 1988-10-04 1990-04-11 Eli Lilly And Company Method for the purification of vitamin K-dependent proteins

Also Published As

Publication number Publication date
HU9502846D0 (en) 1995-12-28
NO953883D0 (no) 1995-09-29
AU6423994A (en) 1994-10-24
PL310887A1 (en) 1996-01-08
CZ253395A3 (en) 1996-01-17
US5700914A (en) 1997-12-23
HUT72712A (en) 1996-05-28
TW278079B (enExample) 1996-06-11
ZA941956B (en) 1994-09-30
FI954649A7 (fi) 1995-09-29
IL109164A0 (en) 1994-06-24
FI954649L (fi) 1995-09-29
FI954649A0 (fi) 1995-09-29
CA2159313A1 (en) 1994-10-13
NO953883L (no) 1995-11-28
WO1994022905A1 (en) 1994-10-13
AU677309B2 (en) 1997-04-17
JPH08508264A (ja) 1996-09-03
CN1121723A (zh) 1996-05-01
EP0691984A1 (en) 1996-01-17
DK38293D0 (da) 1993-03-31

Similar Documents

Publication Publication Date Title
CN1039231C (zh) 因子vii的纯化
JP3459416B2 (ja) 修飾されたファクター▲ｖｉｉ▼
JP5025868B2 (ja) 可逆的に不活性な酸性化プラスミン組成物の調製法
US7767647B2 (en) Method of the invention preparations of factor IXa
CN1261280A (zh) 改进的加工活化c蛋白的方法
CN1080658A (zh) 蛋白质c衍生物
EP2504349B1 (en) Method of purifying pegylated proteins
JP3963406B2 (ja) 因子ＶＩＩおよび活性化因子ＶＩＩａの精製法
JP2010512753A (ja) 延長されたｉｎｖｉｖｏ半減期を有する第ＶＩＩａ因子−（ポリ）シアル酸結合体
KR20010049991A (ko) 혈액 응고 인자 ⅷ를 활성화시키는 프로테아제, 이의프로효소 또는 이들 단백질의 혼합물을 친화성크로마토그래피에 의해 순수한 형태로 제조하는 방법
JPH10509436A (ja) 被阻害形態の被活性化血液因子の生成方法
CN102239175A (zh) 多肽的纯化
CA2105282C (en) Preparation of factor ix
JPH1059866A (ja) 血液凝固第ｖｉｉ因子及び／もしくは活性化血液凝固第ｖｉｉ因子の製造方法
CN1123639C (zh) 人活性蛋白c及其制备方法
CN1167808C (zh) 纤维蛋白溶酶原激活剂的反相hplc分析
CN1210061C (zh) 一种稳定蛋白质c或活性蛋白质c的方法以及由此所得的稳定化组合物
JPH08112095A (ja) 組換えｉｘ因子から組換えプロｉｘ因子の分離方法
EP3512940B1 (en) Process for plasminogen purification starting from human plasma
JP4680329B2 (ja) 血管障害の治療方法
US5198534A (en) Process for preparation of activated protein c by immobilized aprotinin chromatography
CN1109891A (zh) 防止蛋白质c降解的方法
CN102046653B (zh) 控制多肽修饰反应的方法
JPH1059867A (ja) 血液凝固第ｖｉｉ因子の活性化方法及び該方法に基づく活性化血液凝固第ｖｉｉ因子の製造方法

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C14 Grant of patent or utility model
GR01 Patent grant
C19 Lapse of patent right due to non-payment of the annual fee
CF01 Termination of patent right due to non-payment of annual fee